Orally Disintegrating Tablet Amorphous Drug Dispersion
Solution Overview
Problem
Formulating pharmaceutical dosage forms for drugs with low aqueous solubility and permeability poses challenges, particularly in achieving rapid disintegration and enhanced bioavailability, as existing methods often result in poor stability and limited absorption rates.
Innovation Solution
An orally disintegrating tablet formulation comprising a dispersion of a poorly water-soluble drug and an ionic polymer, where the ionic polymer maintains the drug in a substantially amorphous form, ensuring fast disintegration and enhanced bioavailability, with the polymer present in amounts ranging from 45% to 75% by weight, and incorporating additives or carriers for improved stability and disintegration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the drug is formulated in crystalline form, then physical stability is improved, but solubility and dissolution rate decrease
Solution Approach 1:
The patent changes the physical state parameter of the drug from crystalline to amorphous form. This parameter change increases solubility and dissolution rate by eliminating the crystal lattice structure, while the formulation includes stabilizers to maintain the amorphous state's physical stability during storage.
Solution Approach 2:
The patent creates a composite formulation combining the amorphous drug with excipients and stabilizers. This composite structure provides both the enhanced solubility of the amorphous form and the physical stability needed for long-term storage, resolving the contradiction between solubility and stability.
2Reliability
If particle size is reduced to enhance dissolution rate, then solubility is improved, but flow and handling properties deteriorate
Solution Approach 1:
The patent changes the particle size parameter to a controlled fine particle range (1-10 micrometers) and combines it with amorphous form conversion. This dual parameter change achieves high dissolution rate while the specific size range and amorphous structure maintain adequate flow properties for manufacturing.
3Reliability
If amorphous form is used to enhance solubility, then bioavailability is improved, but physical and chemical stability deteriorates
Solution Approach 1:
The patent formulates the amorphous drug as a composite with specific excipients and stabilizers that protect against chemical degradation. This composite structure maintains the high bioavailability of the amorphous form while providing the chemical stability needed for shelf life through interactions between the drug and formulation components.
Solution Approach 2:
The patent introduces stabilizers and excipients as intermediary substances that protect the chemically reactive amorphous drug from degradation. These intermediaries form protective interactions with the drug, reducing its chemical reactivity while maintaining its enhanced solubility and bioavailability.
4Stability of the object's composition
If conventional solid dosage forms are used, then manufacturing stability is maintained, but disintegration time increases
Solution Approach 1:
The patent changes the formulation parameters to include low-compression-force binders and porous matrix structures that enable rapid water penetration and disintegration. These parameter changes achieve disintegration within seconds while maintaining manufacturing stability through optimized compression protocols and material selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves fast disintegration and enhanced dissolution and bioavailability of poorly soluble drugs, suitable for rapid onset of action and improved patient compliance, with the ionic polymer maintaining the drug in an amorphous form to enhance solubility and stability.
Implementation Method 1
the ionic polymer is present in an amount to maintain the poorly water soluble drug in a substantially amorphous form
Implementation Method 2
a dispersion of a poorly water soluble drug and an ionic polymer
Data Source
AI summary
In some aspects of the present invention is a formulation comprising a solid dispersion or intimate mixture of a poorly water soluble drug and an ionic polymer surprisingly exhibiting fast disintegration of tablet.



